Ultragenyx Resubmits MPS IIIA Gene Therapy Application, Aims for Accelerated Approval

Event summary

  • Ultragenyx resubmitted a Biologics License Application (BLA) for UX111, a gene therapy for Sanfilippo syndrome type A (MPS IIIA), to the U.S. FDA on January 30, 2026.
  • The resubmission addresses concerns raised in a Complete Response Letter (CRL) from July 2025 and includes longer-term clinical data.
  • Ultragenyx anticipates a six-month review period, with a potential PDUFA action date in the third quarter of 2026.
  • The therapy, originally developed by Abeona Therapeutics, aims to be the first approved treatment for MPS IIIA, a rare and fatal genetic disorder.

The big picture

The resubmission represents a crucial step for Ultragenyx, as it seeks to bring a first-in-class therapy to market for a devastating rare disease with a limited patient population (estimated 3,000-5,000 in accessible geographies). The FDA’s decision will not only impact Ultragenyx’s prospects but also serve as a precedent for the accelerated approval pathway for gene therapies targeting other rare neurological disorders. Success here could unlock significant value, while rejection would raise questions about the viability of the AAV9 gene therapy approach for MPS IIIA.

What we're watching

Regulatory Risk
Whether the FDA will accept the resubmission and grant accelerated approval hinges on the perceived robustness of the longer-term clinical data and the completeness of the CMC responses, potentially impacting Ultragenyx's valuation.
Clinical Efficacy
The presentation at WORLDSymposium 2026 will be critical in validating the durability of the treatment effect observed in patients, influencing investor confidence and future development timelines.
Market Adoption
The pace at which physicians and families adopt UX111, if approved, will be influenced by the therapy's demonstrated safety profile and the availability of reimbursement, impacting Ultragenyx's revenue projections.